Preparation and administration of mAb114 for Ebola virus disease (EVD)
2 August 2022
| Toolkit

Overview
Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with mAb114. The most common adverse events (incidence ≥ 20%) are pyrexia, chills, tachycardia, tachypnoea and vomiting. The rate of infusion of mAb114 may be slowed or interrupted if the patient develops any signs of infusion associated events.
WHO Team
Editors
World Health Organization
Number of pages
3
Reference numbers
WHO Reference Number: WHO/EVD/therapeutics/mAb114/Poster_B/2022.1